Biopharmaceutical companies are closely watching bills in Congress that are meant to curb “patent trolls,” even though biopharmas don’t yet have a dog in that fight.
“Patent trolls” are companies whose main business is acquiring patents and filing patent litigations to make money rather than making products. The Innovation Act, which died in the last Congress, and The Support Technology and Research for Our Nation’s Growth Patents Act of 2015 (The STRONG Patents Act) were introduced in the House last month to curb the effect of patent trolls.
Generally, patent trolls haven't been seen as a threat to life sciences companies, although many have warned that these entities may target biopharmas in the near future. And yet the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America opposed the Innovation Act as passed by the House in the last Congress as well as the Senate version of the bill that was ultimately withdrawn. The House bill included such measures as “fee shifting,” also known as “loser pays,” which would require the party that loses the litigation to pay attorneys' fees and court costs.
BIO and PhRMA argued that such legislation could impose substantial burdens on the ability to enforce legitimate patents and thus could decrease the value of patents and weaken the incentives for innovation.
This year, BIO supported the STRONG Patent Act, which doesn’t have a fee-shifting provision. BIO said the bill balances incentives necessary to maintain U.S. leadership in biotech innovation with the creation of high-wage, high-value jobs throughout our country.
A Senate Judiciary Committee hearing on patent litigation abuses held on March 18 and a March 19 hearing of the Senate Committee on Small Business and Entrepreneurship both suggested that the fee-shifting provision of the House bill that caused the concern last year of BIO, PhRMA and enough senators to scuttle the legislation is still a divisive issue this year.
Take a free trial to the Health Law Resource Center to receive industry-leading health law news and analysis.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)